Research.Patient.info
Platinum-Resistant Epithelial Ovarian research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancers that haven't responded to previous chemotherapy. It compares a new drug, nemvaleukin alfa, with an existing cancer drug, pembrolizumab, against standard chemotherapy treatments to see if it helps people live longer.
Italy · Norway · Spain - ongoing, recruitingPhase I and Phase II (Integrated)- Other
KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This study is looking at a new medicine called KAND567, given alongside standard carboplatin chemotherapy, for women with ovarian, fallopian tube, or primary peritoneal cancer that has come back. It aims to see how safe it is and find the best dose.
Denmark · Norway · Sweden